A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Trial Profile

A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Rigosertib (Primary) ; Azacitidine; Azacitidine
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Onconova Therapeutics
  • Most Recent Events

    • 26 Jun 2017 Results in patients with myelodysplastic syndrome (n=40) presented at the 22nd Congress of the European Hematology Association, according to an Onconova Therapeutics media release.
    • 26 Jun 2017 Results published in an Onconova Therapeutics media release.
    • 25 Jun 2017 Results assessing in vitro effects of rigosertib combined with azacitidine or vorinostat on patient bone marrow samples, presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top